Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Group C streptococcal cellulitis, looking deeper than the skin.

Khosravi H, Hou A, Colgrove RC, Behlau I.

JAAD Case Rep. 2018 Sep 18;4(8):818-821. doi: 10.1016/j.jdcr.2018.04.008. eCollection 2018 Sep. No abstract available.

2.

Hospitalizations due to selected infections caused by opportunistic premise plumbing pathogens (OPPP) and reported drug resistance in the United States older adult population in 1991-2006.

Naumova EN, Liss A, Jagai JS, Behlau I, Griffiths JK.

J Public Health Policy. 2016 Dec;37(4):500-513. doi: 10.1057/s41271-016-0038-8.

PMID:
28202928
3.

Antimicrobial Blue Light Therapy for Infectious Keratitis: Ex Vivo and In Vivo Studies.

Zhu H, Kochevar IE, Behlau I, Zhao J, Wang F, Wang Y, Sun X, Hamblin MR, Dai T.

Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):586-593. doi: 10.1167/iovs.16-20272.

4.

Degradation of silk films in multipocket corneal stromal rabbit models.

Ghezzi CE, Wang L, Behlau I, Rnjak-Kovacina J, Wang S, Goldstein MH, Liu J, Marchant JK, Rosenblatt MI, Kaplan DL.

J Appl Biomater Funct Mater. 2016 Jul 26;14(3):e266-76. doi: 10.5301/jabfm.5000274.

PMID:
27230452
5.

Scanning Electron Microscopic Analysis of Biofilm Formation in Explanted Human Boston Type I Keratoprostheses.

Sivaraman KR, Hou JH, Chang JH, Behlau I, Cortina MS, Cruz Jde L.

Cornea. 2016 Jan;35(1):25-9. doi: 10.1097/ICO.0000000000000674.

PMID:
26562818
6.

Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention.

Behlau I, Martin KV, Martin JN, Naumova EN, Cadorette JJ, Sforza JT, Pineda R 2nd, Dohlman CH.

Acta Ophthalmol. 2014 Nov;92(7):e546-55. doi: 10.1111/aos.12309. Epub 2014 Jan 25.

7.

Very low risk of light-induced retinal damage during Boston keratoprosthesis surgery: a rabbit study.

Salvador-Culla B, Behlau I, Sayegh RR, Stacy RC, Dohlman CH, Delori F.

Cornea. 2014 Feb;33(2):184-90. doi: 10.1097/ICO.0000000000000029.

PMID:
24322800
8.

In vitro and in vivo assessment of titanium surface modification for coloring the backplate of the Boston keratoprosthesis.

Paschalis EI, Chodosh J, Spurr-Michaud S, Cruzat A, Tauber A, Behlau I, Gipson I, Dohlman CH.

Invest Ophthalmol Vis Sci. 2013 Jun 4;54(6):3863-73. doi: 10.1167/iovs.13-11714.

PMID:
23661373
9.

Two cases of cosmetic iris implant explantation secondary to uveitis, glaucoma, and corneal decompensation.

Veldman PB, Behlau I, Soriano E, Starling JC, Pineda R.

Arch Ophthalmol. 2012 Jun;130(6):787-9. doi: 10.1001/archophthalmol.2011.2594. No abstract available.

PMID:
22801843
10.

Intraocular pressure measurement by radio wave telemetry.

Todani A, Behlau I, Fava MA, Cade F, Cherfan DG, Zakka FR, Jakobiec FA, Gao Y, Dohlman CH, Melki SA.

Invest Ophthalmol Vis Sci. 2011 Dec 20;52(13):9573-80. doi: 10.1167/iovs.11-7878.

PMID:
22039243
11.

Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials.

Behlau I, Mukherjee K, Todani A, Tisdale AS, Cade F, Wang L, Leonard EM, Zakka FR, Gilmore MS, Jakobiec FA, Dohlman CH, Klibanov AM.

Biomaterials. 2011 Dec;32(34):8783-96. doi: 10.1016/j.biomaterials.2011.08.010. Epub 2011 Sep 7.

12.

Hydroxyapatite for keratoprosthesis biointegration.

Wang L, Jeong KJ, Chiang HH, Zurakowski D, Behlau I, Chodosh J, Dohlman CH, Langer R, Kohane DS.

Invest Ophthalmol Vis Sci. 2011 Sep 22;52(10):7392-9. doi: 10.1167/iovs.11-7601.

13.

Enterobacter amnigenus endophthalmitis.

Westerfeld C, Papaliodis GN, Behlau I, Durand ML, Sobrin L.

Retin Cases Brief Rep. 2009 Fall;3(4):409-11. doi: 10.1097/ICB.0b013e31818a46c0.

14.

Fungal keratitis: changing pathogens and risk factors.

Jurkunas U, Behlau I, Colby K.

Cornea. 2009 Jul;28(6):638-43. doi: 10.1097/ICO.0b013e318191695b.

PMID:
19512908
15.

A drug-eluting contact lens.

Ciolino JB, Hoare TR, Iwata NG, Behlau I, Dohlman CH, Langer R, Kohane DS.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3346-52. doi: 10.1167/iovs.08-2826. Epub 2009 Jan 10.

16.

Microbial biofilms in ophthalmology and infectious disease.

Behlau I, Gilmore MS.

Arch Ophthalmol. 2008 Nov;126(11):1572-81. doi: 10.1001/archopht.126.11.1572.

PMID:
19001227
17.

Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy.

de la Cruz J, Behlau I, Pineda R.

J Cataract Refract Surg. 2007 Jul;33(7):1318-21.

PMID:
17586393
18.

Identification of secreted proteins of Mycobacterium tuberculosis.

Behlau I, Wright A.

Ann N Y Acad Sci. 1996 Oct 25;797:280-1. No abstract available.

PMID:
8993380
19.

PhoP/PhoQ transcriptional repression of Salmonella typhimurium invasion genes: evidence for a role in protein secretion.

Pegues DA, Hantman MJ, Behlau I, Miller SI.

Mol Microbiol. 1995 Jul;17(1):169-81.

PMID:
7476203
20.
21.

The PhoP virulence regulon and live oral Salmonella vaccines.

Miller SI, Loomis WP, Alpuche-Aranda C, Behlau I, Hohmann E.

Vaccine. 1993;11(2):122-5.

PMID:
8438611
22.

OHIO-1 beta-lactamase is part of the SHV-1 family.

Shlaes DM, Currie-McCumber C, Hull A, Behlau I, Kron M.

Antimicrob Agents Chemother. 1990 Aug;34(8):1570-6.

23.
24.

Supplemental Content

Loading ...
Support Center